Medicine Questions
follow
https://www.askgileadmedical.com/
Report an Adverse Event
follow
/utility/contact/report-an-adverse-event
Investors
follow
http://investors.gilead.com
Contact
follow
/utility/contact
Canada
follow
/utility/global-operations/north-america/canada
Mexico
follow
/utility/global-operations/north-america/mexico
USA
follow
/About/US-Locations
Argentina
follow
/utility/global-operations/south-america/argentina
Brazil
follow
/utility/global-operations/south-america/brazil
China
follow
/utility/global-operations/asia/china
Hong Kong
follow
/utility/global-operations/asia/hong-kong
India
follow
/utility/global-operations/asia/india
Japan
follow
/utility/global-operations/asia/japan
Korea
follow
/utility/global-operations/asia/korea
Singapore
follow
/utility/global-operations/asia/singapore
Taiwan
follow
/utility/global-operations/asia/taiwan
Israel
follow
/utility/global-operations/middle-east/israel
Turkey
follow
/utility/global-operations/middle-east/turkey
United Arab Emirates
follow
/utility/global-operations/middle-east/united-arab-emirates
Saudi Arabia
follow
/utility/global-operations/middle-east/saudi-arabia
South Africa
follow
/utility/global-operations/africa/south-africa
Australia New Zealand
follow
/utility/global-operations/australia/australia-new-zealand
Austria
follow
/utility/global-operations/europe/austria
Belgium Luxembourg
follow
/utility/global-operations/europe/belgium-luxembourg
Czech Republic & Slovakia
follow
/utility/global-operations/europe/czech-republic-and-slovakia
Denmark
follow
/utility/global-operations/europe/denmark
Finland
follow
/utility/global-operations/europe/finland
France
follow
/utility/global-operations/europe/france
Germany
follow
https://www.gileadsciences.de/
Greece
follow
/utility/global-operations/europe/greece
Iceland
follow
/utility/global-operations/europe/iceland
Ireland
follow
/utility/global-operations/europe/ireland
Italy
follow
/utility/global-operations/europe/italy
Netherlands
follow
/utility/global-operations/europe/netherlands
Norway
follow
/utility/global-operations/europe/norway
Poland & The Baltics
follow
/utility/global-operations/europe/poland
Portugal
follow
/utility/global-operations/europe/portugal
Russia
follow
/utility/global-operations/europe/russia
Spain
follow
https://www.gilead.es/
Sweden
follow
/utility/global-operations/europe/sweden
Switzerland
follow
/utility/global-operations/europe/switzerland
United Kingdom
follow
https://www.gilead.co.uk/
Mission and Core Values
follow
/purpose/mission-and-core-values
Partnerships and Community
follow
/purpose/partnerships-and-community
Inclusion and Diversity
follow
/purpose/inclusion-and-diversity
Corporate Giving
follow
/purpose/giving
Sustainability
follow
/purpose/sustainability
Advancing Global Health
follow
/purpose/advancing-global-health
Medication Access
follow
/purpose/medication-access
Leadership
follow
/about/leadership
U.S. Locations
follow
/about/us-locations
How We Operate
follow
/about/how-we-operate
Ethics and Code of Conduct
follow
/about/ethics-and-code-of-conduct
Science & Medicine
follow
#
Medicines
follow
/science-and-medicine/medicines
Pipeline
follow
/science-and-medicine/pipeline
Research
follow
/science-and-medicine/research
Clinical Trials
follow
https://www.gileadclinicaltrials.com/
Events
follow
http://investors.gilead.com/events
Newsroom
follow
/news-and-press/press-room
Company Statements
follow
/news-and-press/company-statements
Annual Reports
follow
/news-and-press/annual-report
Careers at Gilead
follow
/careers/careers-at-gilead
Our Culture
follow
/careers/our-culture
Meet Our Employees
follow
/careers/meet-our-employees
Inclusion and Diversity in Hiring
follow
/careers/inclusion-and-diversity-in-hiring
Compensation, Benefits and Wellbeing
follow
/careers/compensation-benefits-and-wellbeing
Our Global Footprint
follow
/careers/our-global-footprint
Early Career Opportunities
follow
/careers/early-career-opportunities
Hiring Events
follow
https://gilead.yello.co/external/events_central
Talent Community Sign-up
follow
https://gilead.yello.co/external/form/24a8oU4jF5UL3CKq7lO_Cg
Privacy Statements
follow
/privacy-statements
Terms Of Use
follow
/terms-of-use
Social Media Guidelines
follow
/social-media-guidelines
EU Data Disclosure
follow
/eu-data-disclosure
BACK TO MAIN MENU
follow
#
Partnerships and Community
follow
/purpose/partnerships-and-community
COMPASS Initiative
follow
/purpose/partnerships-and-community/compass
HepConnect
follow
/purpose/partnerships-and-community/hepconnect
HIV Age Positively
follow
/purpose/partnerships-and-community/hiv-age-positively
Lift
follow
/purpose/partnerships-and-community/gilead-lift
RADIAN
follow
/purpose/partnerships-and-community/radian
TRANScend
follow
/purpose/partnerships-and-community/transcend
BACK TO MAIN MENU
follow
#
Corporate Giving
follow
/purpose/giving
What We Fund
follow
/purpose/giving/what-we-fund
Funding Requests
follow
/purpose/giving/funding-requests
Gilead Foundation
follow
/purpose/giving/gilead-foundation
Gilead Public Health Award
follow
/purpose/giving/gilead-public-health-award
BACK TO MAIN MENU
follow
#
Sustainability
follow
/purpose/sustainability
Our Business Is Sustainable
follow
/purpose/sustainability/our-business-is-sustainable
Performance
follow
/purpose/sustainability/performance
Reporting
follow
/purpose/sustainability/reporting
U.N. Global Compact
follow
/purpose/sustainability/un-global-compact
U.N. Sustainable Development Goals
follow
/purpose/sustainability/un-sustainable-development-goals
BACK TO MAIN MENU
follow
#
Advancing Global Health
follow
/purpose/advancing-global-health
COVID-19
follow
/purpose/advancing-global-health/covid-19
HCV Elimination
follow
/purpose/advancing-global-health/hcv-elimination
BACK TO MAIN MENU
follow
#
Medication Access
follow
/purpose/medication-access
U.S. Patient Access
follow
/purpose/medication-access/us-patient-access
Disaster Product Replacement
follow
/purpose/medication-access/disaster-product-replacement
Global Access
follow
/purpose/medication-access/global-access
Authorized Distributors
follow
/purpose/medication-access/authorized-distributors
BACK TO MAIN MENU
follow
#
How We Operate
follow
/about/how-we-operate
Governance
follow
/about/how-we-operate/governance
Transparency
follow
/about/how-we-operate/transparency
BACK TO MAIN MENU
follow
#
Ethics and Code of Conduct
follow
/about/ethics-and-code-of-conduct
Policies
follow
/about/ethics-and-code-of-conduct/policies
Disclosures
follow
/about/ethics-and-code-of-conduct/disclosures
Anti-Counterfeiting
follow
/about/ethics-and-code-of-conduct/anti-counterfeiting
Consumer Product Safety
follow
/about/ethics-and-code-of-conduct/consumer-product-safety
Supplier Information
follow
/about/ethics-and-code-of-conduct/supplier-info
Anti-Bribery and Anti-Corruption Policy
follow
/about/ethics-and-code-of-conduct/anti-bribery-and-anti-corruption
Political Contributions
follow
/about/ethics-and-code-of-conduct/political-contributions
BACK TO MAIN MENU
follow
#
Research
follow
/science-and-medicine/research
Research Scholars Program
follow
/science-and-medicine/research/rsp
Compassionate Use
follow
/science-and-medicine/research/compassionate-use
Investigator-Sponsored Research
follow
/science-and-medicine/research/investigator-sponsored-research
BACK TO MAIN MENU
follow
#
Newsroom
follow
/news-and-press/press-room
Press Releases
follow
/news-and-press/press-room/press-releases
Media Inquiries
follow
/news-and-press/press-room/press-faqs
BACK TO MAIN MENU
follow
#
Company Statements
follow
/news-and-press/company-statements
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union
follow
/news-and-press/company-statements/gilead-announces-decision-not-to-pursue-marketing-authorization-for-descovy-for-pre-exposure-prophylaxis-in-the-european-union
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer
follow
/news-and-press/company-statements/gilead-statement-on-new-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-recommendation-for-sacituzumab-govitecan-hziy-trodelvy-in-second-line-and-later-metastatic-triple-negative-breast-cancer
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
follow
/news-and-press/company-statements/gilead-sciences-statement-on-requiring-vaccination-against-covid-19-for-employees
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
follow
/news-and-press/company-statements/gilead-warns-of-counterfeit-hiv-medication-being-distributed-in-the-united-states
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis
follow
/news-and-press/company-statements/gilead-sciences-statement-on-positive-phase-3-ambition-study-findings-for-the-treatment-of-hiv-associated-cryptococcal-meningitis
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
follow
/news-and-press/company-statements/gilead-sciences-response-to-open-letter-regarding-access-to-ambisome-liposomal-amphotericin-b
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer
follow
/news-and-press/company-statements/gilead-statement-on-new-england-journal-of-medicine-publication-of-positive-phase-3-ascent-study-of-trodelvy-in-metastatic-triple-negative-breast-cancer
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19
follow
/news-and-press/company-statements/gilead-sciences-statement-on-phase-3-veklury-remdesivir-study-in-high-risk-non-hospitalized-patients-with-covid-19
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
follow
/news-and-press/company-statements/gilead-announces-additional-updates-to-the--advancing--access-patient-assistance-medication-assistance-program
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
follow
/news-and-press/company-statements/gilead-announces-updates-to-the-advancing-access-patient-assistance-medication-assistance-program
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services
follow
/news-and-press/company-statements/gilead-announces-plans-for-new-location-in-north-carolinas-research-triangle-region-dedicated-to-business-services
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
follow
/news-and-press/company-statements/gilead-sciences-statement-on-the-passing-of-the-honorable-george-p-shultz-phd
Gilead Sciences Statement on Recent Events in Washington, D.C.
follow
/news-and-press/company-statements/gilead-sciences-statement-on-recent-events-in-washington-dc
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®
follow
/news-and-press/company-statements/gilead-announces-new-arm-of-hiv-womens-prevention-study
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
follow
/news-and-press/company-statements/gilead-sciences-statement-on-updated-veklury-covid19-treatment-guidelines
follow
/news-and-press/company-statements/gilead-sciences-update-on-veklury-remdesivir-manufacturing-network
follow
/news-and-press/company-statements/gilead-sciences-statement-on-state-attorneys-general-letter-on-remdesivir
BACK TO MAIN MENU
follow
#
Annual Reports
follow
/news-and-press/annual-report
Year in Review 2020
follow
/news-and-press/annual-report/year-in-review-2020
BACK TO MAIN MENU
follow
#
Privacy Statements
follow
/privacy-statements
Cookie Statement
follow
/privacy-statements/cookie-statement
BACK TO MAIN MENU
follow
#
Social Media Guidelines
follow
/social-media-guidelines
Linkedin Guidelines
follow
/social-media-guidelines/linkedin-guidelines
Twitter Guidelines
follow
/social-media-guidelines/twitter-guidelines
BACK TO MAIN MENU
follow
#
Canada
follow
/utility/global-operations/north-america/canada
Mexico
follow
/utility/global-operations/north-america/mexico
USA
follow
/About/US-Locations
Argentina
follow
/utility/global-operations/south-america/argentina
Brazil
follow
/utility/global-operations/south-america/brazil
China
follow
/utility/global-operations/asia/china
Hong Kong
follow
/utility/global-operations/asia/hong-kong
India
follow
/utility/global-operations/asia/india
Japan
follow
/utility/global-operations/asia/japan
Korea
follow
/utility/global-operations/asia/korea
Singapore
follow
/utility/global-operations/asia/singapore
Taiwan
follow
/utility/global-operations/asia/taiwan
Israel
follow
/utility/global-operations/middle-east/israel
Turkey
follow
/utility/global-operations/middle-east/turkey
United Arab Emirates
follow
/utility/global-operations/middle-east/united-arab-emirates
Saudi Arabia
follow
/utility/global-operations/middle-east/saudi-arabia
South Africa
follow
/utility/global-operations/africa/south-africa
Australia New Zealand
follow
/utility/global-operations/australia/australia-new-zealand
Austria
follow
/utility/global-operations/europe/austria
Belgium Luxembourg
follow
/utility/global-operations/europe/belgium-luxembourg
Czech Republic & Slovakia
follow
/utility/global-operations/europe/czech-republic-and-slovakia
Denmark
follow
/utility/global-operations/europe/denmark
Finland
follow
/utility/global-operations/europe/finland
France
follow
/utility/global-operations/europe/france
Germany
follow
https://www.gileadsciences.de/
Greece
follow
/utility/global-operations/europe/greece
Iceland
follow
/utility/global-operations/europe/iceland
Ireland
follow
/utility/global-operations/europe/ireland
Italy
follow
/utility/global-operations/europe/italy
Netherlands
follow
/utility/global-operations/europe/netherlands
Norway
follow
/utility/global-operations/europe/norway
Poland & The Baltics
follow
/utility/global-operations/europe/poland
Portugal
follow
/utility/global-operations/europe/portugal
Russia
follow
/utility/global-operations/europe/russia
Spain
follow
https://www.gilead.es/
Sweden
follow
/utility/global-operations/europe/sweden
Switzerland
follow
/utility/global-operations/europe/switzerland
United Kingdom
follow
https://www.gilead.co.uk/
BACK TO MAIN MENU
follow
#
Contact
follow
/utility/contact
Request Medicines Information
follow
https://www.askgileadmedical.com/
Report an Adverse Event
follow
/utility/contact/report-an-adverse-event
Partnership Request
follow
/utility/contact/partnership-request
Medicine Questions
follow
https://www.askgileadmedical.com/
Report an Adverse Event
follow
/utility/contact/report-an-adverse-event
Investors
follow
http://investors.gilead.com
Global Operations
follow
#
Toggle Inner Dropdown
follow
#
follow
/careers/careers-at-gilead#video
See if you’re ready to join a company with a track record of addressing serious illnesses and public health issues around the world.
follow
/careers/careers-at-gilead#video
Advancing Global Health We invest in programs that aim to eliminate some of the world’s most challenging public health threats, enable access to medicines and help fight the stigma that prevents people from seeking care.
follow
/purpose/advancing-global-health
Sustainability We prioritize minimizing our environmental impact and reducing our consumption of natural resources across all of our operations.
follow
/purpose/sustainability
Partnerships and Community We"re working with organizations around the world to eliminate healthcare inequities and promote social justice.
follow
/purpose/partnerships-and-community
Our Mission
follow
/purpose/mission-and-core-values
Culture The Importance of Self Advocacy in Breast Cancer: Janelle’s Story Stories@Gilead - October 21, 2021
follow
https://stories.gilead.com:443/articles/the-importance-of-self-advocacy-in-breast-cancer
Culture Four Questions with Sadé Clacken Joseph: Using Film as a Change Agent Stories@Gilead - October 14, 2021
follow
https://stories.gilead.com:443/articles/four-questions-with-sade-clacken-joseph
Community Putting Faith into Conversations About HIV in the Southern United States Stories@Gilead - October 12, 2021
follow
https://stories.gilead.com:443/articles/putting-faith-into-conversations-about-hiv-in-the-southern-united-states
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
follow
/news-and-press/press-room/press-releases/2021/10/gilead-and-merck-initiate-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-lenacapavir-and-investigational-islatravir-fo
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
follow
/news-and-press/press-room/press-releases/2021/10/gilead-presents-long-term-switch-data-reinforcing-biktarvy-as-a-treatment-option-for-a-broad-range-of-people-living-with-hiv
follow
https://twitter.com/GileadSciences?ref_src=twsrc%5Etfw
We"re Hiring
follow
/careers/careers-at-gilead
Partnerships and Community
follow
/purpose/partnerships-and-community
Pipeline
follow
/science-and-medicine/pipeline
Medicines
follow
/science-and-medicine/medicines
Job Search
follow
/careers/careers-at-gilead
Contact Us
follow
/utility/contact
Report an Adverse Event
follow
/utility/contact/report-an-adverse-event
Press Room
follow
/news-and-press/press-room
Investor Calls
follow
http://investors.gilead.com
Privacy Statement
follow
/privacy-statements
Terms of Use
follow
/terms-of-use
EU Data Disclosure
follow
/eu-data-disclosure
Social Media Guidelines
follow
/social-media-guidelines
Modern Slavery Act Statement
follow
/-/media/files/pdfs/other/modern-slavery-statement.pdf
follow
https://twitter.com/GileadSciences
follow
https://www.linkedin.com/company/gilead-sciences/
follow
https://www.facebook.com/GileadSciences
follow
https://www.youtube.com/channel/UCNSt7PtsfNGbezR9hmvRI1w